# HLCS

## Overview
The HLCS gene encodes the enzyme holocarboxylase synthetase, which is integral to biotin metabolism. This enzyme is classified as a ligase, specifically responsible for catalyzing the biotinylation of several biotin-dependent carboxylases, including acetyl-CoA carboxylase and pyruvate carboxylase. These carboxylases are crucial for metabolic pathways such as fatty acid synthesis and gluconeogenesis. Holocarboxylase synthetase operates in both the mitochondria and cytoplasm, highlighting its role in diverse cellular processes (LeónDelRio1995Isolation). The HLCS gene's mutations can lead to holocarboxylase synthetase deficiency, a condition that disrupts normal metabolic functions and is characterized by multiple carboxylase deficiency (Morrone2002Clinical). This disorder is often responsive to biotin supplementation, underscoring the enzyme's critical function in maintaining metabolic homeostasis (Suzuki2005Mutations).

## Structure
Holocarboxylase synthetase (HLCS) is a protein involved in biotin metabolism, consisting of 726 amino acids. The primary structure includes a homologous region to BirA, the biotin apo-carboxyl carrier protein ligase of Escherichia coli, which is thought to be the biotin-binding region (Suzuki2005Mutations). The minimum functional HLCS protein is retained in the last 349 amino acids, indicating that the N-terminal region is not essential for biotinylating activity (Morrone2002Clinical).

The secondary structure of HLCS includes alpha helices and beta sheets, typical of proteins involved in enzymatic functions. The tertiary structure involves the three-dimensional folding of the protein, which includes specific domains such as the biotin-binding domain. This domain contains a consensus sequence of six residues, highly conserved and similar to the BirA protein of Escherichia coli (Morrone2002Clinical).

HLCS does not have a quaternary structure involving multiple subunits, as it functions as a single polypeptide chain. The gene likely generates multiple transcripts, with at least three mRNA types identified, starting at different exons, although these variations do not change the amino acid sequence of HLCS (Suzuki2005Mutations).

## Function
Holocarboxylase synthetase (HLCS) is an enzyme that plays a critical role in biotin metabolism by catalyzing the biotinylation of several biotin-dependent carboxylases. These carboxylases include acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and methylcrotonyl-CoA carboxylase, which are essential for various metabolic pathways such as fatty acid synthesis, gluconeogenesis, and amino acid catabolism (Morrone2002Clinical; Suzuki2005Mutations). HLCS is active in both the mitochondria and cytoplasm, indicating its involvement in multiple cellular compartments and processes (LeónDelRio1995Isolation).

The enzyme functions by attaching biotin to specific lysine residues on these carboxylases, a modification necessary for their enzymatic activity (Pendini2008Microbial). This biotinylation process involves a two-step reaction where biotin is first activated to biotinyl-5′-AMP in an ATP-dependent manner before being transferred to the target enzyme (Pendini2008Microbial). The proper functioning of HLCS ensures the activation of these carboxylases, which is crucial for maintaining normal metabolic functions and energy production in human cells (Bailey2008Reduced). Deficiencies in HLCS activity can lead to metabolic disorders, highlighting its importance in cellular metabolism (Morrone2002Clinical).

## Clinical Significance
Mutations in the HLCS gene lead to holocarboxylase synthetase deficiency, a rare autosomal recessive disorder characterized by multiple carboxylase deficiency (MCD). This condition results from impaired biotinylation of carboxylases, leading to reduced enzymatic activity essential for metabolism. Symptoms typically manifest in the neonatal period or early infancy and include metabolic acidosis, organic aciduria, lethargy, hypotonia, seizures, and dermatitis (Morrone2002Clinical; Suzuki2005Mutations). 

The disorder is biotin-responsive, with patients often showing improvement upon biotin administration, although some may continue to excrete abnormal metabolites (Suzuki2005Mutations). Specific mutations, such as p.L216R, result in a catalytically inactive enzyme, leading to severe MCD and poor response to biotin therapy (Morrone2002Clinical; Bailey2008Reduced). Other mutations, like p.R508W and p.V363D, have been identified in various populations and are associated with similar clinical manifestations (Wu2020Impaired; Ling2023Clinical).

Early diagnosis through newborn screening and timely biotin supplementation are crucial for preventing severe metabolic crises and ensuring positive clinical outcomes (Ling2023Clinical). The HLCS gene's mutation spectrum correlates with clinical phenotypes, aiding in diagnosis and management (Zheng2020Clinical).

## Interactions
Holocarboxylase synthetase (HLCS) is known to interact with histones, particularly histone H3, to mediate biotinylation at lysine residues K9 and K18. This interaction is crucial for chromatin structure and function, influencing gene regulation and genome stability. The interaction between HLCS and histone H3 has been confirmed through various experimental methods, including co-immunoprecipitation and limited proteolysis assays, which demonstrate that HLCS protects histone H3 from proteolytic degradation (Bao2011Holocarboxylase).

HLCS also interacts with biotin-dependent carboxylases, such as acetyl-CoA carboxylase and pyruvate carboxylase, facilitating their activation by catalyzing the attachment of biotin. This interaction is essential for the proper functioning of these enzymes in metabolic pathways (Esaki2011Effects).

In addition to protein interactions, HLCS may interact with nucleic acids, potentially influencing gene expression. This interaction is suggested by the enzyme's involvement in epigenetic pathways, where it plays a role in transcriptional repression through histone biotinylation (Esaki2011Effects). These interactions highlight the multifaceted role of HLCS in cellular metabolism and gene regulation.


## References


[1. (Wu2020Impaired) Hsin-Ru Wu, Kuan-Jung Chen, Hui-Pin Hsiao, and Mei-Chyn Chao. Impaired glucose homeostasis and a novel hlcs pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review. Journal of Pediatric Endocrinology and Metabolism, 33(11):1481–1486, August 2020. URL: http://dx.doi.org/10.1515/jpem-2020-0106, doi:10.1515/jpem-2020-0106. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/jpem-2020-0106)

[2. (LeónDelRio1995Isolation) A León-Del-Rio, D Leclerc, B Akerman, N Wakamatsu, and R A Gravel. Isolation of a cdna encoding human holocarboxylase synthetase by functional complementation of a biotin auxotroph of escherichia coli. Proceedings of the National Academy of Sciences, 92(10):4626–4630, May 1995. URL: http://dx.doi.org/10.1073/pnas.92.10.4626, doi:10.1073/pnas.92.10.4626. This article has 87 citations.](https://doi.org/10.1073/pnas.92.10.4626)

[3. (Ling2023Clinical) Shiying Ling, Wenjuan Qiu, Huiwen Zhang, Lili Liang, Deyun Lu, Ting Chen, Xia Zhan, Yu Wang, Xuefan Gu, and Lianshu Han. Clinical, biochemical, and genetic analysis of 28 chinese patients with holocarboxylase synthetase deficiency. Orphanet Journal of Rare Diseases, March 2023. URL: http://dx.doi.org/10.1186/s13023-023-02656-y, doi:10.1186/s13023-023-02656-y. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-023-02656-y)

[4. (Suzuki2005Mutations) Yoichi Suzuki, Xue Yang, Yoko Aoki, Shigeo Kure, and Yoichi Matsubara. Mutations in the holocarboxylase synthetase genehlcs. Human Mutation, 26(4):285–290, 2005. URL: http://dx.doi.org/10.1002/humu.20204, doi:10.1002/humu.20204. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20204)

[5. (Morrone2002Clinical) A. Morrone, S. Malvagia, M.A. Donati, S. Funghini, F. Ciani, I. Pela, A. Boneh, H. Peters, E. Pasquini, and E. Zammarchi. Clinical findings and biochemical and molecular analysis of four patients with holocarboxylase synthetase deficiency. American Journal of Medical Genetics, 111(1):10–18, May 2002. URL: http://dx.doi.org/10.1002/ajmg.10532, doi:10.1002/ajmg.10532. This article has 33 citations.](https://doi.org/10.1002/ajmg.10532)

[6. (Bailey2008Reduced) Lisa M. Bailey, Ruby A. Ivanov, Sarawut Jitrapakdee, Callum J. Wilson, John C. Wallace, and Steven W. Polyak. Reduced half-life of holocarboxylase synthetase from patients with severe multiple carboxylase deficiency. Human Mutation, 29(6):E47–E57, 2008. URL: http://dx.doi.org/10.1002/humu.20766, doi:10.1002/humu.20766. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20766)

[7. (Pendini2008Microbial) Nicole R. Pendini, Lisa M. Bailey, Grant W. Booker, Matthew C. Wilce, John C. Wallace, and Steven W. Polyak. Microbial biotin protein ligases aid in understanding holocarboxylase synthetase deficiency. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1784(7–8):973–982, July 2008. URL: http://dx.doi.org/10.1016/j.bbapap.2008.03.011, doi:10.1016/j.bbapap.2008.03.011. This article has 28 citations.](https://doi.org/10.1016/j.bbapap.2008.03.011)

[8. (Esaki2011Effects) Shingo Esaki, Sridhar A Malkaram, and Janos Zempleni. Effects of single-nucleotide polymorphisms in the human holocarboxylase synthetase gene on enzyme catalysis. European Journal of Human Genetics, 20(4):428–433, October 2011. URL: http://dx.doi.org/10.1038/ejhg.2011.198, doi:10.1038/ejhg.2011.198. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2011.198)

[9. (Zheng2020Clinical) Zhenzhu Zheng, Gaopin Yuan, Minyan Zheng, Yiming Lin, Faming Zheng, Mengyi Jiang, Lin Zhu, and Qingliu Fu. Clinical, biochemical, and genetic analysis of a chinese han pedigree with holocarboxylase synthetase deficiency: a case report. BMC Medical Genetics, July 2020. URL: http://dx.doi.org/10.1186/s12881-020-01080-4, doi:10.1186/s12881-020-01080-4. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12881-020-01080-4)

[10. (Bao2011Holocarboxylase) Baolong Bao, Valerie Pestinger, Yousef I. Hassan, Gloria E.O. Borgstahl, Carol Kolar, and Janos Zempleni. Holocarboxylase synthetase is a chromatin protein and interacts directly with histone h3 to mediate biotinylation of k9 and k18. The Journal of Nutritional Biochemistry, 22(5):470–475, May 2011. URL: http://dx.doi.org/10.1016/j.jnutbio.2010.04.001, doi:10.1016/j.jnutbio.2010.04.001. This article has 33 citations.](https://doi.org/10.1016/j.jnutbio.2010.04.001)